San Diego, CA -- (SBWIRE) -- 05/29/2013 -- An investigation on behalf of investors of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) shares over potential securities laws violations by AMAG Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.

Investors who purchased shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), have certain options and should contact the Shareholders Foundation at mail(at)shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) concerning whether a series of statements by AMAG Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

AMAG Pharmaceuticals, Inc. reported that its annual Total Revenue increased from $17.18 million in 2009 to $85.38 million in 2012 and that its respective Net Loss declined from $93.35 million to $16.75 million.

NASDAQ:AMAG shares grew from slightly over $15 per share in Jan. 2013 to as high as $23.85 per share in late March 2013.

Then on May 21, 2013, AMAG Pharmaceuticals, Inc. announced that it has been made aware by Takeda Pharma AG, the exclusive product distributor of ferumoxytol in Switzerland, that it is recalling one specific batch of Rienso® (ferumoxytol) from the Swiss market.

Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) declined from $25.14 per share on May 21, 2013 to as low as $21.76 per share on May 24, 2013.

On May 28, 2013, NASDAQ:AMAG shares closed at $22.24 per share.

Those who purchased shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Trevor Allen
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com